The goal of this clinical trial is to find out if an artificial intelligence (AI)-enabled stratified management platform can help adults with coronary heart disease (CHD) better perform exercise rehabilitation and manage their health after being discharged from the hospital. The main questions it aims to answer are:
1. Does using the AI platform lead to a greater improvement in exercise capacity (measured by peak oxygen consumption, VO2peak) after 3 months? 2. Does the platform help increase daily physical activity, improve exercise adherence and motivation, and better control modifiable cardiovascular risk factors? 3. Is guiding home-based exercise with this platform safe for low-risk CHD patients?
Researchers will compare the AI Management Group (using the platform and a sports wristband) to the Routine Management Group (receiving usual care without the platform) to see if the AI group shows more significant improvements in fitness and health metrics.
Participants will:
1. Be randomly assigned to either use the AI platform or receive usual post-discharge care. 2. Receive a personalized exercise prescription from a doctor before going home. 3. If in the AI group: Use the smartphone app and wearable device to track health data for comprehensive post-discharge management, and receive reminders and immediate safety alerts. 4. Attend a follow-up visit at 3 months for check-ups and tests, including an exercise test and health assessments.
The study hopes to show that this intelligent management platform is an effective and safe tool to help people with CHD recover at home, stay active, and reduce future heart risks.
CHD patients aged over 18 years;
Stratified as low-risk for cardiovascular events during exercise and classified as low-risk according to the GRACE risk score.
Ability of the patient or close relatives to use smartphones and applications;
Willingness to participate and sign the informed consent form.
Residual stenosis of >50% in the left main coronary artery, or >70% stenosis in other major epicardial vessels;
Planned coronary revascularization within the next 3 months;
Acute myocardial infarction within the past 1 month;
Severe cognitive impairment;
China National Center for Cardiovascular Diseases
Lead sponsor
Chinese Academy of Medical Sciences
Collaborator